Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel
Introduction: Praziquantel (PZQ) is the only commercially available drug for schistosomiasis. The current shortage of alternative effective drugs and the lack of successful preventive measures enhance its value. The increase in the prevalence of PZQ resistance under sustained drug pressure is, there...
Main Authors: | Eglal I. Amer, Iman Fathy Abou-El-Naga, Laila M. Boulos, Heba S. Ramadan, Salwa S. Younis |
---|---|
Format: | Article |
Language: | English |
Published: |
Instituto Nacional de Salud
2022-03-01
|
Series: | Biomédica: revista del Instituto Nacional de Salud |
Subjects: | |
Online Access: | https://revistabiomedica.org/index.php/biomedica/article/view/5913 |
Similar Items
-
Altered Response of Strain of Schistosoma mansoni to Oxamniquine and Praziquantel
by: Patrícia Ivana Pires Bonesso-Sabadini, et al.
Published: (2002-04-01) -
Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting
by: Amara RO, et al.
Published: (2018-08-01) -
Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni
by: Naglaa Mohamed El-Lakkany, et al.
Published: (2011-11-01) -
Efeito do praziquantel incorporado a lipossomas nos diferentes estágios de desenvolvimento dos ovos de Schistosoma mansoni
by: T.F. Frezza, et al.
Published: (2007-05-01) -
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of <i>Schistosoma mansoni</i> Infection
by: Omary Mashiku Minzi, et al.
Published: (2021-04-01)